Sanofi Cost Of Revenue vs Income Before Tax Analysis

SNY Stock

USD 48.72 0.44 0.91%

Sanofi ADR financial indicator trend analysis is much more than just breaking down Sanofi ADR prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sanofi ADR is a good investment. Please check the relationship between Sanofi ADR Cost Of Revenue and its Income Before Tax accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sanofi ADR Cost Of Revenue account and Income Before Tax. At this time, the significance of the direction appears to have strong relationship.

The correlation between Sanofi ADR's Cost Of Revenue and Income Before Tax is 0.6. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Sanofi ADR, assuming nothing else is changed. The correlation between historical values of Sanofi ADR's Cost Of Revenue and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Sanofi ADR are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Cost Of Revenue i.e., Sanofi ADR's Cost Of Revenue and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.6

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Sanofi ADR income statement and represents the costs associated with goods and services Sanofi ADR provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Sanofi ADR income statement and is an important metric when analyzing Sanofi ADR profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Sanofi ADR's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sanofi ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.At this time, Sanofi ADR's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 203.7 M in 2024, despite the fact that Discontinued Operations is likely to grow to (110.3 M).

	2021	2022	2023	2024 (projected)
Gross Profit	26.9B	31.7B	31.8B	22.0B
Total Revenue	39.2B	45.4B	46.0B	31.3B

Gross Profit Total Revenue

Sanofi ADR fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets
Total Assets		0.88	0.55	0.93	0.99	0.97	0.66	0.84	0.78	0.99	0.13	0.69	0.85	1.0	0.87	0.25	-0.61	0.91	0.97	0.38	-0.16	0.98	0.42	0.9	0.6	0.79
Short Long Term Debt Total	0.88		0.47	0.85	0.81	0.8	0.86	0.75	0.75	0.85	-0.06	0.71	0.7	0.88	0.6	0.09	-0.37	0.89	0.88	0.31	-0.4	0.94	0.2	0.83	0.6	0.69
Other Current Liab	0.55	0.47		0.71	0.56	0.43	0.24	0.7	0.57	0.5	0.67	0.62	0.16	0.54	0.4	-0.11	0.0	0.31	0.62	0.53	0.15	0.51	0.76	0.61	0.24	0.4
Total Current Liabilities	0.93	0.85	0.71		0.92	0.85	0.6	0.94	0.81	0.89	0.23	0.77	0.67	0.92	0.7	-0.02	-0.35	0.74	0.96	0.52	-0.14	0.9	0.46	0.92	0.57	0.64
Total Stockholder Equity	0.99	0.81	0.56	0.92		0.97	0.56	0.84	0.78	0.98	0.16	0.7	0.84	0.99	0.88	0.27	-0.6	0.86	0.97	0.38	-0.07	0.95	0.45	0.9	0.58	0.78
Property Plant And Equipment Net	0.97	0.8	0.43	0.85	0.97		0.61	0.75	0.71	0.97	0.08	0.61	0.88	0.97	0.91	0.3	-0.66	0.9	0.92	0.32	-0.07	0.94	0.38	0.85	0.63	0.8
Net Debt	0.66	0.86	0.24	0.6	0.56	0.61		0.56	0.31	0.7	-0.03	0.26	0.6	0.66	0.47	-0.05	-0.32	0.8	0.63	0.06	-0.42	0.77	0.17	0.47	0.52	0.7
Accounts Payable	0.84	0.75	0.7	0.94	0.84	0.75	0.56		0.67	0.82	0.3	0.65	0.57	0.84	0.59	-0.15	-0.26	0.62	0.91	0.38	-0.2	0.8	0.49	0.77	0.4	0.59
Cash	0.78	0.75	0.57	0.81	0.78	0.71	0.31	0.67		0.69	-0.07	0.98	0.54	0.78	0.52	0.24	-0.28	0.63	0.81	0.49	-0.21	0.75	0.15	0.93	0.44	0.39
Non Current Assets Total	0.99	0.85	0.5	0.89	0.98	0.97	0.7	0.82	0.69		0.15	0.6	0.87	0.99	0.88	0.24	-0.63	0.92	0.95	0.28	-0.14	0.97	0.44	0.83	0.6	0.85
Non Currrent Assets Other	0.13	-0.06	0.67	0.23	0.16	0.08	-0.03	0.3	-0.07	0.15		-0.06	-0.06	0.11	0.32	-0.33	-0.12	-0.03	0.17	0.1	0.28	0.08	0.95	0.05	-0.05	0.15
Cash And Short Term Investments	0.69	0.71	0.62	0.77	0.7	0.61	0.26	0.65	0.98	0.6	-0.06		0.41	0.7	0.4	0.17	-0.11	0.52	0.76	0.5	-0.16	0.67	0.13	0.88	0.4	0.32
Net Receivables	0.85	0.7	0.16	0.67	0.84	0.88	0.6	0.57	0.54	0.87	-0.06	0.41		0.85	0.84	0.38	-0.82	0.88	0.73	0.16	-0.25	0.85	0.23	0.7	0.63	0.74
Good Will	1.0	0.88	0.54	0.92	0.99	0.97	0.66	0.84	0.78	0.99	0.11	0.7	0.85		0.86	0.25	-0.6	0.91	0.97	0.36	-0.18	0.98	0.41	0.9	0.58	0.79
Common Stock Total Equity	0.87	0.6	0.4	0.7	0.88	0.91	0.47	0.59	0.52	0.88	0.32	0.4	0.84	0.86		0.33	-0.85	0.83	0.78	0.27	0.01	0.83	0.59	0.71	0.48	0.72
Common Stock Shares Outstanding	0.25	0.09	-0.11	-0.02	0.27	0.3	-0.05	-0.15	0.24	0.24	-0.33	0.17	0.38	0.25	0.33		-0.46	0.34	0.08	0.14	0.09	0.21	-0.16	0.23	0.11	0.33
Short Term Investments	-0.61	-0.37	0.0	-0.35	-0.6	-0.66	-0.32	-0.26	-0.28	-0.63	-0.12	-0.11	-0.82	-0.6	-0.85	-0.46		-0.69	-0.45	-0.07	0.23	-0.59	-0.34	-0.46	-0.29	-0.46
Non Current Liabilities Total	0.91	0.89	0.31	0.74	0.86	0.9	0.8	0.62	0.63	0.92	-0.03	0.52	0.88	0.91	0.83	0.34	-0.69		0.83	0.22	-0.32	0.96	0.27	0.77	0.55	0.8
Inventory	0.97	0.88	0.62	0.96	0.97	0.92	0.63	0.91	0.81	0.95	0.17	0.76	0.73	0.97	0.78	0.08	-0.45	0.83		0.38	-0.14	0.95	0.43	0.9	0.54	0.72
Other Current Assets	0.38	0.31	0.53	0.52	0.38	0.32	0.06	0.38	0.49	0.28	0.1	0.5	0.16	0.36	0.27	0.14	-0.07	0.22	0.38		0.05	0.37	0.19	0.64	0.1	0.05
Other Stockholder Equity	-0.16	-0.4	0.15	-0.14	-0.07	-0.07	-0.42	-0.2	-0.21	-0.14	0.28	-0.16	-0.25	-0.18	0.01	0.09	0.23	-0.32	-0.14	0.05		-0.27	0.23	-0.2	0.11	0.07
Total Liab	0.98	0.94	0.51	0.9	0.95	0.94	0.77	0.8	0.75	0.97	0.08	0.67	0.85	0.98	0.83	0.21	-0.59	0.96	0.95	0.37	-0.27		0.37	0.89	0.6	0.79
Property Plant And Equipment Gross	0.42	0.2	0.76	0.46	0.45	0.38	0.17	0.49	0.15	0.44	0.95	0.13	0.23	0.41	0.59	-0.16	-0.34	0.27	0.43	0.19	0.23	0.37		0.31	0.17	0.4
Total Current Assets	0.9	0.83	0.61	0.92	0.9	0.85	0.47	0.77	0.93	0.83	0.05	0.88	0.7	0.9	0.71	0.23	-0.46	0.77	0.9	0.64	-0.2	0.89	0.31		0.51	0.52
Short Term Debt	0.6	0.6	0.24	0.57	0.58	0.63	0.52	0.4	0.44	0.6	-0.05	0.4	0.63	0.58	0.48	0.11	-0.29	0.55	0.54	0.1	0.11	0.6	0.17	0.51		0.63
Intangible Assets	0.79	0.69	0.4	0.64	0.78	0.8	0.7	0.59	0.39	0.85	0.15	0.32	0.74	0.79	0.72	0.33	-0.46	0.8	0.72	0.05	0.07	0.79	0.4	0.52	0.63

Click cells to compare fundamentals

Sanofi ADR Account Relationship Matchups

Sanofi ADR fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	112.6B	114.4B	120.2B	126.7B	126.5B	88.7B
Short Long Term Debt Total	26.0B	23.7B	22.4B	21.2B	18.4B	13.7B
Other Current Liab	6.5B	11.3B	10.9B	11.7B	13.4B	14.0B
Total Current Liabilities	20.4B	19.3B	21.3B	24.0B	24.2B	14.4B
Total Stockholder Equity	59.1B	63.1B	68.7B	74.8B	74.0B	50.5B
Property Plant And Equipment Net	11.0B	10.6B	12.0B	11.7B	11.8B	8.5B
Net Debt	16.5B	9.8B	12.3B	8.5B	9.7B	7.6B
Accounts Payable	5.3B	4.0B	6.2B	6.8B	7.3B	3.7B
Cash	9.4B	13.9B	10.1B	12.7B	8.7B	6.2B
Non Current Assets Total	83.7B	80.6B	89.6B	92.6B	95.8B	66.5B
Non Currrent Assets Other	992M	1.1B	1.1B	1.2B	13.6B	14.3B
Cash And Short Term Investments	9.9B	14.8B	11.2B	13.4B	9.0B	7.1B
Net Receivables	10.1B	7.5B	7.6B	10.7B	8.4B	7.4B
Good Will	44.5B	44.4B	48.1B	49.9B	49.4B	33.9B
Common Stock Shares Outstanding	1.3B	2.5B	2.5B	2.5B	1.3B	2.5B
Short Term Investments	426M	900M	1.1B	664M	270M	256.5M
Liabilities And Stockholders Equity	112.6B	114.4B	120.2B	126.7B	126.5B	88.7B
Non Current Liabilities Total	33.0B	31.9B	29.9B	27.6B	27.9B	23.6B
Inventory	8.0B	8.4B	8.7B	9.0B	9.7B	5.6B
Other Current Assets	1.0B	4.0B	4.3B	4.0B	3.9B	2.2B
Other Stockholder Equity	(47.8B)	(343M)	(407M)	(581M)	4.1B	4.3B
Total Liab	53.4B	51.2B	51.2B	51.6B	52.1B	38.0B
Property Plant And Equipment Gross	11.0B	10.6B	12.0B	11.7B	27.4B	28.8B
Total Current Assets	28.9B	33.8B	30.7B	34.1B	30.7B	22.2B
Accumulated Other Comprehensive Income	52.5B	56.8B	62.2B	68.2B	67.4B	35.5B
Short Term Debt	4.8B	3.0B	3.5B	4.5B	2.3B	2.9B
Intangible Assets	16.5B	18.3B	21.4B	21.6B	18.3B	17.9B
Other Liab	12.1B	11.4B	11.0B	10.8B	12.5B	11.9B
Current Deferred Revenue	3.8B	252M	319M	264M	597M	567.2M
Retained Earnings	51.8B	60.1B	63.0B	66.7B	67.5B	64.1B
Other Assets	8.8B	11.4B	13.5B	12.9B	14.8B	9.8B
Long Term Debt	20.1B	19.7B	17.1B	14.9B	14.3B	12.7B
Property Plant Equipment	11.0B	10.6B	12.0B	11.7B	13.4B	10.5B
Deferred Long Term Liab	2.3B	6.1B	7.7B	6.2B	7.2B	4.0B
Long Term Investments	5.3B	7.1B	8.0B	9.2B	2.7B	2.5B
Short Long Term Debt	4.6B	2.8B	3.2B	4.2B	2.0B	3.2B
Net Tangible Assets	177M	6.3B	6.9B	9.5B	8.5B	4.6B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sanofi Cost Of Revenue vs Income Before Tax Analysis

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Income Before Tax

Sanofi ADR fundamental ratios Correlations

Sanofi ADR Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sanofi ADR fundamental ratios Accounts

Also Currently Popular

Additional Tools for Sanofi Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Total Assets
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Good Will	+ 0.99	Total Stockholder Equity
Good Will	+ 0.99	Non Current Assets Total
Total Liab	+ 0.98	Total Assets

Short Term Investments	- 0.85	Common Stock Total Equity
Short Term Investments	- 0.82	Net Receivables
Non Current Liabilities Total	- 0.69	Short Term Investments
Short Term Investments	- 0.66	Property Plant And Equipment Net
Short Term Investments	- 0.63	Non Current Assets Total
Short Term Investments	- 0.61	Total Assets